Explore
Validate
Learn
ELISA
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB3481-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human ErbB3/Her3 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human ErbB3/Her3 in ELISAs. Does not cross-react with recombinant EGF R.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
P21860- Isotype
- IgG
- Antibody clone number
- 66223
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Soluble HER3 predicts survival in bladder cancer patients.
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.
Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Memon AA, Gilliver SC, Borre M, Sundquist J, Sundquist K, Nexo E, Sorensen BS
Oncology letters 2018 Feb;15(2):1783-1788
Oncology letters 2018 Feb;15(2):1783-1788
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul MA, Mondon P, Barret JM, Mathis G, Prost JF, Pèlegrin A, Chardès T
Molecular cancer therapeutics 2017 Jul;16(7):1312-1323
Molecular cancer therapeutics 2017 Jul;16(7):1312-1323
Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S, Essapen S, Seddon AM, Modjtahedi H
International journal of oncology 2016 Nov;49(5):1825-1838
International journal of oncology 2016 Nov;49(5):1825-1838
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.
Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, Fanslow W, Hu Z, Sun N, Hasegawa H, Clark R, Foltz IN, Yan W
The Journal of biological chemistry 2015 Mar 20;290(12):7535-62
The Journal of biological chemistry 2015 Mar 20;290(12):7535-62
Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
Fock V, Plessl K, Draxler P, Otti GR, Fiala C, Knöfler M, Pollheimer J
Journal of cell science 2015 Dec 1;128(23):4306-16
Journal of cell science 2015 Dec 1;128(23):4306-16
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H
International journal of oncology 2011 Aug;39(2):483-91
International journal of oncology 2011 Aug;39(2):483-91
Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA
Assay and drug development technologies 2010 Feb;8(1):27-36
Assay and drug development technologies 2010 Feb;8(1):27-36
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ
Oncogene 2008 Sep 4;27(39):5195-203
Oncogene 2008 Sep 4;27(39):5195-203
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 15;14(12):3729-36
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 15;14(12):3729-36
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by NRG1-beta 1/HRG1-beta 1 and Neutralization by Human ErbB3/Her3 Antibody. Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (Catalog # 377-HB) stimulates proliferation in the MCF-17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND50 is typically 0.0075-0.03 µg/mL.
